Evidence map›Paper›PMID 42384087›Full record

ArticleJournal of gastroenterology2026

METTL3/FTO drives ferroptosis in colorectal cancer by targeting m

Zili Zhang, Kaiwen Cheng, Yuyao Wei, Yuqi Sun, Chun Zhang, Yang Wu, Mei Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zili ZhangJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. zilizhang@njucm.edu.cn.
Kaiwen ChengJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Yuyao WeiJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Yuqi SunJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Chun ZhangDepartment of Gastroenterology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210004, China.
Yang WuPancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Mei GuoJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. 370110@njucm.edu.cn.

Funding

National Natural Science Foundation of China 82474164
6 · The paper itself

Abstract

backgroundFerroptosis is a newly defined form of programmed cell death and is associated with the progression of colorectal cancer (CRC). Abnormal levels of N

methodsCRC cell lines were treated with ferroptosis inducers, and m

resultsThe upregulation of METTL3 and downregulation of FTO enhanced m

conclusionsOur findings unveil a crucial mechanism through which YTHDF2 facilitates ferroptotic susceptibility via MUC1 destabilization and subsequent SLC7A11 downregulation. These discoveries open up new possibilities for ferroptosis-regulated therapeutics by offering targets and approaches for the treatment of CRC.

Indexed as

Colorectal cancerFerroptosisM6A methylationMUC1SLC7A11YTHDF2

Identifiers

PMID42384087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.